PHAR’s Ashis K. Das, Eunice Chang, Caleb Paydar, and Michael S. Broder recently published a study examining adherence and persistence in patients with psoriasis and psoriatic arthritis who newly initiated apremilast at the beginning of the COVID-19 pandemic. Their analysis, done in collaboration with Amgen, Inc., compared treatment patterns in patients who initiated treatment via telehealth visits versus the in-person setting. The study found similar medication adherence and persistence in this population during a 6-month follow-up period, suggesting that patients initiating apremilast can be as effectively managed with telehealth visits as with in-person visits. The full manuscript can be found in Dermatology and Therapy or on the PHAR publications page.